SpyGlass Pharma, Inc. - Asset Resilience Ratio
SpyGlass Pharma, Inc. (SGP) has an Asset Resilience Ratio of 4.54% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see SGP total asset value.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how SpyGlass Pharma, Inc.'s Asset Resilience Ratio has changed over time. Read SpyGlass Pharma, Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SpyGlass Pharma, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See SGP days of operational coverage to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.04 Million | 4.54% |
| Total Liquid Assets | $11.04 Million | 4.54% |
Asset Resilience Insights
- Limited Liquidity: SpyGlass Pharma, Inc. maintains only 4.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SpyGlass Pharma, Inc. Industry Peers by Asset Resilience Ratio
Compare SpyGlass Pharma, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX |
Biotechnology | 0.00% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 10.17% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual Asset Resilience Ratio data for SpyGlass Pharma, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.56% | $11.08 Million | $115.87 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $23.32 Million | -- |
| 2023-12-31 | 59.46% | $24.47 Million | $41.15 Million | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more